A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2024-03-05
Target enrollment:
Participant gender:
Summary
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced
solid tumor malignancies who are intolerant of existing therapies known to provide clinical
benefit, have disease that has progressed after standard therapy, or have previously failed
other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to
confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the
safety and efficacy of RSC-1255.